Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a ...

Bright Minds Biosciences (DRUG) added ~10% in the premarket on Tuesday after the company said that its lead asset, BMB-101, ...

Shares of Bright Minds Biosciences rose after the company released positive topline results from its phase two trial of a treatment for patients with drug-resistant Absence Seizures and Developmental ...

BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...

Bright Minds Biosciences ( ($TSE:DRUG) ) has issued an update. On January 5, 2026, Bright Minds Biosciences announced plans to report topline ...

(NewsNation) — March 26 is Purple Day, a day dedicated to raising awareness about epilepsy worldwide. An estimated 50 million people worldwide are diagnosed with epilepsy, and seizures are the main ...

Date and Time: January 6, 2026, 8AM ET Webcast: https://app.livestorm.co/bright-minds-biosciences/bmb-101-topline-data-announcement The call will include a discussion of the data followed by a Q&A ...

The areas of the cerebral cortex that are affected in mice with absence epilepsy have been pinpointed by research that also shows that transplanting embryonic neural cells into these areas can ...

Changes Clinical Practice: In children with absence epilepsy, ethosuximide should be preferred as the first-line anticonvulsant. Childhood absence epilepsy is one of the most common epilepsy syndromes ...

At first, the teacher described her six-year-old student as absentminded, a daydreamer. The boy was having difficulty paying attention in class. As the teacher watched the boy closely, she realized ...